文献速递心境障碍老年精神会诊联络精神医学

经皮雌二醇与睾酮治疗更年期抑郁及情绪症状的回顾性队列研究

Transdermal oestradiol and testosterone therapy for menopausal depression and mood symptoms: retrospective cohort study.
PubMed 文献 · Br J Psychiatry · 2025-06-16

该回顾性队列研究纳入英国最大更年期专科诊所的920名围绝经期和绝经后女性,评估经皮17β-雌二醇±微粒化黄体酮或左炔诺孕酮宫内释放系统,和/或经皮睾酮对抑郁和焦虑症状的影响。启动或优化绝经激素治疗后,平均随访107天,Meno-D评分平均下降44.59%(95% CI -46.83%至-42.34%,P < 0.001),所有方案均改善心理健康,但不同方案间无显著差异。

要点

  • 绝经激素治疗与围绝经期和绝经后女性情绪症状显著改善相关。
  • 不同孕激素类型、是否加用睾酮及优化策略间改善幅度无显著差异。
  • 仍需前瞻性研究和随机临床试验评估不同方案在不同人群中的长期效果。

核心结论

  • 绝经激素治疗的使用与围绝经期和绝经后女性情绪显著改善相关。

研究设计与样本

  • 英国最大更年期专科诊所开展的真实世界回顾性队列研究,纳入920名女性,其中围绝经期448名(48.7%),绝经后435名(47.3%)。
  • 使用Meno-D问卷测量情绪相关症状,评估经皮17β-雌二醇±微粒化黄体酮或左炔诺孕酮宫内释放系统,和/或经皮睾酮的影响。

主要发现

  • 启动或优化绝经激素治疗后,平均随访107天,Meno-D评分平均下降44.59%(95% CI -46.83%至-42.34%,P < 0.001)。
  • 每个情绪症状均显著改善(P < 0.01),围绝经期和绝经后女性均出现改善。
  • 所有绝经激素治疗方案均改善心理健康,包括两种孕激素类型(体同源黄体酮和左炔诺孕酮宫内释放系统)。
  • 启动策略比较:雌二醇±孕激素 vs. 雌二醇±孕激素加睾酮,Meno-D评分分别下降45.38%和48.53%(P = 0.47)。
  • 优化策略比较:较高雌二醇剂量组、加用睾酮组、较高雌二醇剂量加睾酮组分别下降34.70%、43.93%和43.25%(P = 0.38)。

关键数值与推荐

  • Meno-D评分平均下降44.59%(95% CI -46.83%至-42.34%,P < 0.001),平均随访107天。
  • 每个情绪症状改善P < 0.01。
  • 启动策略比较45.38% vs. 48.53%(P = 0.47)。
  • 优化策略比较34.70%、43.93%和43.25%(P = 0.38)。

临床怎么用

  • 对于围绝经期和绝经后女性的情绪症状,绝经激素治疗可能带来显著改善。
  • 不同孕激素类型、是否加用睾酮及优化策略间改善幅度无显著差异,临床可根据患者情况选择方案。

局限性

  • 回顾性队列设计,无法确定因果关系。
  • 平均随访107天,时间较短。
  • 需要前瞻性研究和随机临床试验评估不同方案在不同人群中的长期效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psychological symptoms in perimenopause and early menopause are common. The impact of menopausal hormone therapy (MHT) on menopausal mood symptoms is unclear. AIMS: To assess the impact of 17β-oestradiol ± micronised progesterone or the levonorgestrel-releasing intrauterine device, and/or transdermal testosterone, on depressive and anxiety symptoms in peri- and postmenopausal women. METHOD: A real-world retrospective cohort study set in the largest specialist menopause clinic in the UK. The Meno-D questionnaire measured mood-related symptoms. RESULTS: The study included 920 women: 448 (48.7%) perimenopausal, and 435 (47.3%) postmenopausal. Following initiation/optimisation of MHT, mean Meno-D scores decreased by 44.59% (95% CI -46.83% to -42.34%, P < 0.001) after average 107 days follow-up. Mood symptoms significantly improved (P < 0.01 per symptom). Improvement occurred in peri- and postmenopausal women. All MHT regimens improved mental health including both progestogen types (body-identical progesterone and levonorgestrel-releasing intrauterine device), MHT initiation strategy (oestradiol ± a progestogen versus oestradiol ± a progestogen and testosterone, 45.38 v. 48.53%, respectively, P = 0.47) and MHT optimisation strategy (MHT users treated with a higher oestradiol dose versus testosterone added versus both a higher oestradiol dose and testosterone, 34.70, 43.93 and 43.25%, respectively, P = 0.38). CONCLUSIONS: Use of menopausal hormone therapy was associated with significant improvement in mood in peri- and postmenopausal women. Prospective studies and randomised clinical trials are needed to assess the effects of different regimens in different patient populations over longer time periods.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Glynne S, Kamal A, McColl L, et al. Transdermal oestradiol and testosterone therapy for menopausal depression and mood symptoms: retrospective cohort study. Br J Psychiatry. 2025. PMID: 40519046. doi:10.1192/bjp.2025.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。